Evaluation of D < sub > 1 < /sub > /D < sub > 5 < /sub > Partial Agonist PF-06412562 in Parkinson ’s Disease following Oral Administration

Conclusions: We report the first evidence of potential anti-parkinsonian efficacy of the oral selective D1/D5 partial agonist PF-06412562 without the significant acute changes in cardiovascular parameters reported with previous D1 agonists.Neurodegener Dis 2018;18:262 –269
Source: Neurodegenerative Diseases - Category: Neurology Source Type: research